Akero Therapeutics, 89bio, Boston Pharmaceuticals and more are working to bring novel treatment options for metabolic dysfunction-associated steatohepatitis to a market that could reach $16 billion by ...

New research identifies the liver protein PTPRD as a key regulator of metabolic liver disease. Reduced levels of PTPRD disrupt glucose and lipid metabolism, promote liver fat accumulation, and impair ...

The tool reduces pathologist variability in liver biopsy assessment during trials of treatments for metabolic ...

AI-powered digital pathology specialist PathAI, based in Boston in the US, said that AIM-NASH AI Assist is designed to assist ...

Resmetirom offers a targeted approach to metabolic dysfunction–associated steatohepatitis (MASH) for use alongside lifestyle ...

A new study sheds light on changes to the fetus's bile acid, which affects how liver disease develops and ... Mar. 11, 2025 — Metabolic dysfunction-associated steatohepatitis (MASH) is a ...

The authors used NHANES data to link biomarkers of MASLD and liver fibrosis to create logistic regression models with hepatic ... associated steatohepatitis (MASH) and cirrhosis.